Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from NewAmsterdam Pharma Company ( (NAMS) ).
On June 4, 2025, NewAmsterdam Pharma Company N.V. held its annual general meeting where 74.45% of eligible shares voted. Shareholders approved several proposals, including the adoption of the 2024 annual accounts, discharge of directors’ liabilities, appointment of Deloitte as auditor, and various board appointments. The company also decided to hold annual Say-on-Pay votes until 2031.
The most recent analyst rating on (NAMS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
The overall stock score of 56 reflects mixed financial performance with growth potential overshadowed by current profitability challenges. Technical analysis shows a neutral trend, while the valuation remains strained due to lack of profitability. Positive corporate events, including promising trial results and strategic board appointments, are significant factors supporting the score.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
Average Trading Volume: 922,144
Technical Sentiment Signal: Buy
Current Market Cap: $2.18B
For a thorough assessment of NAMS stock, go to TipRanks’ Stock Analysis page.